# Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

> **NCT02628704** · PHASE2 · WITHDRAWN · sponsor: **Karyopharm Therapeutics Inc**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Placebo (for selinexor)
- **DRUG:** carfilzomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02628704
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-12
- **Primary completion:** 2017-06
- **Final completion:** 2018-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2023-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02628704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02628704, "Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT02628704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*